Gerresheimer's EUR 35 Million Accounting Hit Meets EUR 10 Million Insider Vote of Confidence

Gerresheimer faces accounting shortfall, delayed audits, and SDAX expulsion risk. Insiders invest €10.2M while Jefferies downgrades. Loan extension grants breathing room.

Two powerful camps are pulling Gerresheimer in opposite directions. Inside the boardroom, major shareholders are pouring millions into the stock. Outside, analysts are slashing price targets and the risk of an index expulsion looms. The pharmaceutical packaging group, already reeling from a freshly disclosed accounting shortfall, now faces a battle to restore credibility while insiders signal they see value where the market sees risk.

Forensic scrutiny has identified violations of internal guidelines and IFRS rules in transactions spanning 2024 and 2025. The core issues: inventory valuation and the recognition of bill-and-hold revenues. A second external audit firm has been brought in to investigate. Gerresheimer estimates that the correction needed for 2024 revenue will reach around EUR 35 million, with adjusted EBITDA requiring an adjustment of approximately EUR 24 million. The company is now targeting June 2026 for the release of its audited 2025 consolidated financial statements, overseen by interim CEO Uwe Röhrhoff, who took the helm in November.

On the financing front, Gerresheimer secured a critical reprieve. Holders of EUR 870 million in Schuldschein loans voted 96% in favour of extending the deadline for submitting audited accounts to September 30, 2026. The company's banking partners also supported the extension. As part of the agreement, key leverage-ratio covenants have been suspended through the third quarter of 2026, giving management room to pursue operational restructuring and the planned sale of the Centor Inc. division.

Jefferies delivered a blow on May 19, downgrading the stock from "Buy" to "Hold" and slashing its price target from EUR 34.10 to EUR 26.80. The analysts cited integration risks from the Bormioli Pharma acquisition and persistent weakness in several end markets. The downgrade adds to a growing list of headwinds: the delayed audited figures make an exit from the SDAX index increasingly probable, and the annual general meeting, originally scheduled for April, has been postponed indefinitely.

Yet even as Jefferies turned cautious, the company’s supervisory board member Klaus Röhrig acted decisively. Two investment vehicles linked to his circle—AOC Gecko and the Active Ownership Fund—snapped up a combined 361,000 shares on May 12 via XETRA. AOC Gecko acquired roughly 271,000 shares, while Active Ownership Fund added another 90,000. The average purchase price came to EUR 28.25 per share, well above the prevailing market level at the time. The total outlay of around EUR 10.2 million represents a clear bet that the company is fundamentally undervalued.

The stock has since recovered to around EUR 27.00, but remains 58% below its 52-week high of EUR 64.40. Earlier this week, it traded as low as EUR 25.88 before bouncing. Over the past 30 days, the share price has gained roughly 17%, though it has lost nearly 7% year to date. The market capitalisation stands at approximately EUR 894 million, and the shares are hovering just above the 200-day moving average of EUR 26.98.

The gulf between insider conviction and analyst scepticism is now unusually wide. The Active Ownership Fund had previously stepped in with purchases near the EUR 28 level, providing a floor. But with the true extent of the accounting corrections still unknown—and no reliable valuation base until the forensic audit concludes—the stock remains in a volatile no-man's land. The next quarterly results will be closely watched for signs that the Bormioli integration is on track, while the countdown to the June 2026 audit deadline adds a layer of regulatory pressure that no amount of insider buying can fully erase.